TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON was delisted on the 27th of June, 2024.
24 hedge funds and large institutions have $23.2M invested in TRACON Pharmaceuticals, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 8 closing their positions.
112% more capital invested
Capital invested by funds: $10.9M → $23.2M (+$12.2M)
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
11% less funds holding
Funds holding: 27 → 24 (-3)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$204K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$139K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$65K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$32.5K |
| 5 |
Jane Street
New York
|
+$18.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TI
Telemetry Investments
New York
|
-$406K |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$158K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$62K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$57K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$27K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Dimensional Fund Advisors
Austin,
Texas
| – | -$57K | -449 | Closed |
|
|
27
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$27K | -217 | Closed |
|
28
Citadel Advisors
Miami,
Florida
| – | -$17K | -132 | Closed |
|
|
QF
29
QVT Financial
New York
| – | -$15K | -117 | Closed |
|
|
VF
30
Virtu Financial
New York
| – | -$11K | -91 | Closed |
|
31
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$4K | -31 | Closed |
|
TCON Hedge Fund Activity: Q1 2019 in Review
24 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q1 2019, worth a combined $23.2M — up 112% from $10.9M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of TCON and 5 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 5 added.
The largest buyer was Renaissance Technologies, adding an estimated $204K. The largest seller was Telemetry Investments, cutting an estimated $406K.
- 24 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q1 2019, down from 27 in Q4 2018.
- Funds reported $23.2M of TRACON Pharmaceuticals, Inc. Common Stock stock for Q1 2019, up 112% quarter-over-quarter.
- 5 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q1 2019 and 8 closed out, a net change of -3 holders.
- The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q1 2019 was Renaissance Technologies, an estimated $204K added.
- The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q1 2019 was Telemetry Investments, an estimated $406K sold.
Based on aggregated 13F filings for Q1 2019.